Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

This study is looking into new ways to treat a type of lung cancer called non-small cell lung cancer (NSCLC) that has either spread or is advanced. NSCLC is the most common kind of lung cancer. The researchers want to see how well a new drug called telisotuzumab adizutecan works when given along with other drugs that help boost the body's immune system, like budigalimab or pembrolizumab. These immune-boosting drugs, known as PD-1 immune checkpoint inhibitors, aim to help your body's own immune system recognise and fight cancer cells.

The study has two main parts. In the first part, participants will receive telisotuzumab adizutecan along with budigalimab at different doses, starting with lower amounts and gradually increasing. This helps the doctors find a dose that is both well-tolerated and likely to be effective. Once a suitable dose is found, the second part of the study will begin. Here, some participants will receive the new drug combination, while others will receive the standard treatment currently used for this type of lung cancer, which usually involves pembrolizumab, pemetrexed, and a chemotherapy drug like carboplatin or cisplatin.

The main reasons for this study are to check for any side effects from these new drug combinations and to see how much they can reduce or control the cancer's activity. By comparing the new treatments to standard care, researchers hope to find better and safer treatment options for adult patients with advanced NSCLC who haven't had previous treatment for their advanced cancer and don't have certain specific genetic changes in their tumour. This research is important for potentially developing more effective ways to fight lung cancer.